
    
      This is a prospective randomized, double-blind, placebo controlled, parallel group, Phase 2
      study. Subjects meeting selection criteria will be randomly assigned to receive 12 weeks
      twice daily (BID) dosing with FK614 or placebo. Enrollment for this study will be
      approximately 200 patients.
    
  